Two Democratic lawmakers, Kathy Castor from Florida and Terri Sewell from Alabama, have introduced a bill aimed at reversing a decision made by the Trump administration to end a Medicare prescription drug subsidy program. The bill, known as the Affordable Premiums for Seniors Act, seeks to extend the Medicare Part D Premium Stabilization Demonstration until 2029.

The introduction of this measure comes on the heels of the Trump administration’s announcement that the Centers for Medicare & Medicaid Services (CMS) would discontinue the program by the end of the following year. Kathy Castor emphasized the growing financial strain on seniors, stating, “Every trip to the grocery store and every monthly bill is increasingly painful for my older neighbors. The added strain of higher prescription drug costs is the last thing they need.” She expressed her commitment to fighting against the recent scheme by the Department of Health and Human Services (HHS) to increase costs, advocating for affordable and dependable Medicare benefits.

Why It Matters

According to data from KFF, in 2026, nearly 25 million individuals were enrolled in standalone Medicare Part D prescription drug plans. Without the stabilization program, beneficiaries could face steeper premium rises in 2027 than seen in previous years. Retirees living on fixed incomes already contend with rising housing and healthcare costs. Proponents argue maintaining the subsidy would ensure drug coverage remains affordable, countering the Trump administration’s view that additional subsidies are unnecessary.

What to Know

The Affordable Premiums for Seniors Act aims to prevent CMS from terminating the Medicare Part D Premium Stabilization Demonstration, proposing to extend the program through 2029. Initially created after reforms were enacted under the Inflation Reduction Act, the subsidy introduced a $2,000 cap on out-of-pocket prescription drug costs while shifting more cost burdens to Part D plans.

Finance expert Michael Ryan highlighted the situation, noting, “This is about what they pay each month for standalone Part D drug coverage. The stabilization program absorbed some of the shock while insurers adjusted to major changes in Medicare Part D. Ending it removes that cushion.” Kevin Thompson, CEO of 9i Capital Group, stated, “Lowering premiums for people at the lower end of the income spectrum, particularly those who rely heavily on prescription drugs, is a definite benefit for beneficiaries living on fixed incomes.” However, he pointed out a counterargument that the focus should be on addressing the underlying costs of drugs and healthcare.

Data from the Medicare Payment Advisory Commission (MedPAC) showed that the subsidy saved seniors an average of $312 in 2026, supporting the notion that every dollar counts for those on fixed incomes. Terri Sewell remarked, “Ending the Part D Premium Stabilization Program could mean higher premiums and greater financial strain for millions of seniors. The Affordable Premiums for Seniors Act will help ensure that Medicare beneficiaries have the stability and certainty they deserve.”

The Trump Administration’s Perspective

CMS, under the leadership of Mehmet Oz, reviewed plan bids for 2027 and assessed that insurers are now experienced enough to operate under the redesigned Part D benefit. Oz justified the decision, suggesting the additional subsidies functioned as an unnecessary bailout, claiming, “We are stabilizing the market so this bailout is no longer needed.” CMS stated premiums will rise by less than $10 for most Medicare recipients, with some experiencing lower premiums.

The underlying argument from CMS is that the subsidy served as a temporary solution, not intended to be permanent. According to expert Michael Ryan, continuing subsidies shifts costs back to taxpayers and might hinder normal market pricing. Ryan questioned, “The question moving forward is whether the market is actually ready to lose the training wheels.”

What Happens Next

The bill faces hurdles in a Republican-controlled Congress, requiring approval from both houses before reaching the President’s desk. Meanwhile, Medicare beneficiaries anticipate final premium announcements for 2027, which will provide insight into potential cost increases following the end of the stabilization program. As Thompson noted, extending the subsidy will be challenging without bipartisan support.